Lilly Hid Cymbalta ‘Brain Zap’ Risk, Plaintiff Says

Eli Lilly & Co. misled consumers about the frequency of “brain zaps” and other withdrawal symptoms tied to its antidepressant Cymbalta, an attorney for plaintiff Claudia Herrera told a federal jury in California in the first trial targeting the drug (Herrera v. Eli Lilly & Co., C.D. Cal., 13-02702, opening statements 12/4/14).

Lilly officials failed to provide proper warnings that Cymbalta, once the company’s top-selling drug, carried with it severe withdrawal risks, T. Matthew Leckman told jurors in the U.S. District Court for the Central District of California.

Herrera claims she suffered electrical-shock sensations, dizziness and nausea ...